News

Julio Rosenstock, MD Lead Author of Phase 2 Trial Results Evaluating Orforglipron Published in Diabetes, Obesity and Metabolism

Julio Rosenstock, MD, was the lead author of Phase 2 trial results evaluating orforglipron, an oral GLP-1 receptor agonist, published in Diabetes, Obesity and Metabolism. The study found that orforglipron doses of 12 mg and higher significantly improved β-cell function and insulin sensitivity in participants with type 2 diabetes (T2D). These results support orforglipron’s potential … Read more

Velocity Appoints Dr. Sarah Smiley as Chief Physician Officer

Velocity Clinical Research is pleased to announce the appointment of Sarah Smiley, DO, FACP, as its new Chief Physician Officer (CPO), reinforcing the company’s commitment to clinical leadership as it continues to grow its global site network and deepen its therapeutic expertise. Dr. Smiley is a seasoned physician investigator with nearly two decades of experience … Read more

Velocity Appoints Ines Abs as Country Head for Germany, Strengthening European Leadership Amid Market Consolidation

Velocity Clinical Research, the world’s leading integrated research site organization, has appointed Ines Abs as its new Country Head of Germany, reinforcing its commitment to growth in Europe at a time when other site networks are retreating from the region. Ines brings over two decades of experience in clinical research operations, having held senior leadership … Read more

Velocity Clinical Research Partners with Palantir to Solve Clinical Trials’ Payment Headache

Velocity Clinical Research, the leading fully integrated site organization, has announced a strategic partnership with Palantir Technologies to automate and streamline the notoriously complex payments reconciliation process in clinical trials. This collaboration marks a milestone in applying advanced artificial intelligence (AI) to one of the industry’s most persistent administrative challenges. Reconciling invoices and payments in … Read more

Velocity Recognized as a Top Enrolling Site Network in Q1 2025 by AstraZeneca

We’re proud to share that Velocity was named a top enrolling site network for Q1 2025 by AstraZeneca, with the highest number of randomizations across their biopharma portfolio. This recognition is a testament to the dedication of our teams around the world who work every day to ensure clinical trial participants are supported, engaged, and … Read more

Douglas K. Logan, MD, and David Ensz, MD, Author Nature Communications Article

Velocity Principal Investigators Douglas K. Logan, MD, and David Ensz, MD, are authors of a newly published Nature Communications article, “Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase.” The Phase 1/2 Moderna trial results “demonstrate the proof of concept that mRNA-1020 and mRNA-1030 elicit similar HA-specific immune responses to [hemagglutinin] HA-only … Read more

An interview with Daniel Williams, DO on Velocity’s PIVOT program and training the next generation of Principal Investigators

Very few physicians begin their careers with an eye on research. Moving into the role of Principal Investigator (PI) can be unexpectedly challenging, with demands that often take physicians by surprise. “Much of my experience with clinical research centered around reviewing journal articles for clinical practice,” explains Daniel Williams, DO, FAAEM, who transitioned from emergency … Read more

Could clinical trials be a safe healthcare space for the LGBTQ+ community?

By Stephanie Anderson, Chief of Staff Representation in clinical trials is crucial for equitable healthcare. Yet, the nature of clinical trial sites, which have historically been based in municipal centers where patient populations are highest, automatically excludes huge swathes of the population, such as those living in rural areas. These sites are also rarely positioned … Read more

Dr. Rosenstock is the Lead Investigator for Lilly’s ACHIEVE-1 Trial for Oral GLP-1, Orforglipron, Results Published in NEJM

Tremendous results! Julio Rosenstock, MD, recently authored and presented results for Lilly’s Phase 3 ACHIEVE-1 trial. The once-daily pill significantly reduced A1C (1.3-1.6%) and led to an average 16-pound weight loss. The results were presented by Dr. Rosenstock at the American Diabetes Association Scientific Sessions and published in The New England Journal of Medicine. “The … Read more